Phase 3 N=511 Convalescent Plasma in Outpatients With COVID-19
Covid19
Primary: Number of Patients With Disease Progression (Intention-to-treat Population) — 77; 81; 51; 56 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
COVID19 · Diabetes Mellitus · Hypertension
Primary: Overall Survival — 33; 39 Participants — p=0.027
N/A N=162 Brief COVID-19 Intervention for People With Serious Mental Illness and Co-Morbid Medical Conditions
Mental Illness · Chronic Disease
Primary: Number of Participants Who Received COVID-19 Vaccine — 56; 50 Participants
Phase 3 N=114 Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
Covid19
Primary: Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS. — 7; 7; 2; 2 days — p=0.05
N/A N=463 Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema
Primary: Absolute Change From Baseline at Week 156 in Adjusted Lung Density (ALD) Based on Percentile Density at 15% (PD15) Adjusted for Lung Volume — -0.27; -3.15; -5.04; -4.74…
Phase 2 N=81 Cardiovascular Effects of COVID-19
COVID-19
Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days
Phase 2 N=32 COVID Protection After Transplant-Immunosuppression Reduction
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
N/A N=3,632 Epidemiological Study of the COVID-2019 in Participating Organizations.
Covid19
Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person
Phase 2 N=34 Extension Study in a Cohort of Adult Patients With COVID-19 Infection
COVID-19 Infection
Primary: Number and Percentage of Participants With Complications Related to Post COVID-19 Infection — 4; 8; 5; 17 Participants
Phase 3 N=1,187 The Prevent Severe COVID-19 (PRESECO) Study
Covid19
Primary: Number of Participants With Sustained Clinical Recovery — 425; 475 Participants
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Phase 2 N=66 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
COVID-19
Primary: Participants With a Disease Control Status Defined as no Disease Progression to Severe. — 30; 26 Participants
Phase 2 N=32 Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
COVID-19
Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants
Phase 4 N=31 Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
Phase 2 N=142 Impact of Colchicine and Low-dose Naltrexone on COVID-19
Covid19
Primary: In Patients Hospitalized With Moderate COVID-19, the Impact of Colchicine and LDN, Alone or in Combination, on Achieving Disease Recovery by Day 5. — 22; 24; 20; 18…
N/A N=1,277,747 COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
Immunocompromised · Immunosuppressed · Covid-19
Primary: Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection — 0.89; 0.34 Events per 100 person-years
Phase 3 N=14,001 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern
SARS-CoV-2 Infection · HIV Infections · COVID-19
Primary: Part A: Number of Participants With a First Occurrence of CDC-defined COVID-19 Starting 1 Day After Month 0 Dose Until Month 6 Dose in FAS Cohort Between Analysis Group…
N/A N=2,005 Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China
Pulmonary Disease, Chronic Obstructive
Primary: Main Cohort: Change From Baseline in Pre-bronchodilator and Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Month 30 — -158.9; -93.9; -1.2; -17.3…
N/A N=554 COVID-19 Treatment Cascade Optimization Study
COVID-19
Primary: Completion of COVID-19 Test — 72; 60 Participants
N/A N=1,075 Special Investigation of COMIRNATY in the Population With Underlying Diseases
COVID-19
Primary: Proportion of Participants With Adverse Reactions — 59; 30; 39 Participants
Phase 3 N=19 A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
COVID-19
Primary: Number of Participants Who Progress by at Least One Level Higher on the Modified WHO Ordinal Scale — 0; 0; 0; 0 Participants
Phase 3 N=4,044 ACTIV-2: A Study for Outpatients With COVID-19
Coronavirus · Covid19
Primary: COVID-19 Symptom Duration (Phase 2) — 21.0; 18.5; 24.0; 20.5 Days
Phase 1 N=9 Maraviroc in Patients With Moderate and Severe COVID-19
COVID
Primary: Rate of Completion — 7 Participants
Phase 2 N=80 An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness
Respiratory Viral Infection · Antiviral Treatment · COVID-19
Primary: Number of Participants With Viral Illness — 12; 30 Participants
Phase 2 N=132 MP1032 Treatment in Patients With Moderate to Severe COVID-19
COVID-19
Primary: Percentage of Participants With Disease Progression Using National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale at Day 14 — 9.8; 11.6…
Phase 2 N=50 Sarilumab for Patients With Moderate COVID-19 Disease
COVID
Primary: Number of Participants With Intubation or Death — 5; 1 Participants
Phase 2 N=120 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
Covid19
Primary: For Clinical Domain: Time-to-sustained-resolution — 26; NA days — p=0.07
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
Phase 2 N=38 Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Confirmed Coronavirus Disease
Primary: Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7 — 6; 0; 20; 8 Participants — p=0.0346
Phase 3 N=1,323 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Covid19 · SARS-CoV Infection
Primary: Clinical Progression to Severe Covid — 154; 179; 105; 96 Participants